Breaking News, Collaborations & Alliances

Boehringer Provides CMC Services for CANbridge

Supplies clinical material manufactured in China for new cancer drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Beijing-based CANbridge Life Sciences has received clinical trial application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with its drug candidate CAN017. Boehringer Ingelheim’s biopharmaceutical contract manufacturing business, known as Boehringer Ingelheim BioXcellence, is providing the chemistry, manufacturing, and control (CMC) services for CAN017 since the collaboration started in August 2016. Boehringer Ingelheim BioChina su...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters